KYNB

$7.04-$0.06 (-0.85%)live

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institution

Market cap

$28.7M

4M shares

52-week range

$6.32 – $9.70

21% from low

Sector

PHARMACEUTICAL PREPARATIONS

Exchange

NASDAQ

Change$-2.46

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$10M	+47.3%	$-13.75	$-15.37–$-12.41	—	3
2027	$9M	-11.5%	$-11.44	$-14.85–$-7.57	—	3
2028	$9M	-2.5%	$-12.45	$-17.92–$-7.76	—	3
2029	$12M	+36.8%	$-22.29	$-35.10–$-12.13	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 4 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-13	$-3.18	$-4.68	-47.2%
2026-05-11	$-3.36	$-3.74	-11.3%
2026-03-16	$-3.89	$-3.61	+7.2%
2025-11-10	$-4.01	$-1.61	+59.9%
2025-08-11	$-2.25	$-3.38	-50.2%
2025-05-12	$0.75	$-4.00	-633.3%
2025-03-17	$-0.08	$-0.08	+0.0%
2024-11-12	$-0.38

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
KYNBKyntra Bio, Inc.	$7.10	+0.42%	$29M	—
ALGSAligos Therapeutics, Inc.	$7.00	-3.85%	$43M	—
ATNMActinium Pharmaceuticals, Inc.	$0.82	+3.53%	$26M	—
CELUCelularity Inc.	$0.69	-1.46%	$20M	—
KZRKezar Life Sciences, Inc.	$7.29	+0.00%

Kyntra Bio, Inc. Common Stock

Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.

www.kyntrabio.com

Employees: 34
IPO / List date: Nov 14, 2014
HQ: SAN FRANCISCO, CA

Held by traders on TradeandTell

No one on the platform currently holds KYNB.

Super investors & insiders

Institutions holding (13F)

Institution	Shares	Reported
Renaissance Technologiesas of 2026-03-31	27,481	$186.3K

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded KYNB yet.

$KYNB chatter on StockTwits

Estimize@Estimize12h
$KYNB reports after the close, Estimize Consensus +0.24 EPS and -0.10M Revs compared to WS http://www.estimize.com/kynb/fq2-2026?utm_conten
View on StockTwits ↗
DEN K@ARKADIY_PAROVOZOV13h
$KYNB Kyntra Bio reports Q2 2026 financial results today (August 13) after market close, followed by a conference call at 5:00 PM ET. Looking forward to any updates on the Phase 3 roxadustat protocol and FG-3246 progress.
View on StockTwits ↗
DEN K@ARKADIY_PAROVOZOV1d
$KYNB New real-world study published in Clinical and Experimental Nephrology (Aug 2026): Roxadustat was associated with a significantly lower incidence of peritoneal dialysis-associated peritonitis compared to rhuEPO (adjusted IRR 0.494, p=0.041). Suggests possible protective effects of HIF stabilization beyond anemia correction. Positive safety signal in PD patients. https://link.springer.com/article/10.1007/s10157-026-02926-6
View on StockTwits ↗
DEN K@ARKADIY_PAROVOZOV1d
$KYNB New paper in Frontiers in Cell and Developmental Biology (Aug 2026) discusses hypoxia-driven cardiac fibrosis after myocardial infarction. Roxadustat is mentioned positively for enhancing HIF signaling, promoting reparative M2 macrophage polarization, and potentially attenuating adverse cardiac remodeling. Interesting additional biological context for the HIF-PHI class beyond anemia. https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2026.1814166/full
View on StockTwits ↗
Estimize@Estimize2d
Wall St is expecting -3.18 EPS for $KYNB Q2 [Reporting 08/13 AMC] http://www.estimize.com/intro/kynb?chart=historical&metric_name=eps&utm_c
View on StockTwits ↗
Estimize@Estimize2d
Wall St is expecting -3.33 EPS for $KYNB Q3 [Reporting 11/09 AMC] http://www.estimize.com/intro/kynb?chart=historical&metric_name=eps&utm_c
View on StockTwits ↗
DEN K@ARKADIY_PAROVOZOV2d
$KYNB New market analysis projects the Roxadustat market to reach $9.56 billion by 2030 (CAGR 6.9%), driven by rising anemia prevalence, preference for oral therapies, and growing adoption of HIF-PHIs in CKD. https://www.openpr.com/news/4597106/analysis-of-key-market-segments-driving-the-roxadustat-market
View on StockTwits ↗
DEN K@ARKADIY_PAROVOZOV3d
$KYNB Phase 3 Roxadustat trial in LR-MDS with high transfusion burden (NCT07722988) is listed on ClinicalTrials.Veeva. Sponsored by Kyntra Bio, ~201 patients planned, status: begins enrollment in ~7 months. https://ctv.veeva.com/study/a-study-to-investigate-the-efficacy-and-safety-of-roxadustat-fg-4592-for-treating-anemia-in-partic
View on StockTwits ↗
DEN K@ARKADIY_PAROVOZOV3d
$KYNB Kyntra Bio’s Q2 2026 financial results are scheduled for Thursday, August 13 (after market close). Conference call at 5:00 PM ET. https://investor.kyntrabio.com/news-releases/news-release-details/kyntra-bio-report-second-quarter-2026-financial-results
View on StockTwits ↗
Mike Salinaro@mjtwins16Aug 6
$KYNB https://clinicaltrials.gov/study/NCT07722988
View on StockTwits ↗
Maximo@MaxMiamiFlAug 5
$KYNB this think should be at least 100m MC. Lets not forget it was close to a billion market cap...at one point.
View on StockTwits ↗
DEN K@ARKADIY_PAROVOZOVAug 5
$KYNB Positive preclinical data (Aug 3, 2026): a new nanoparticle formulation of Roxadustat significantly improved antifibrotic efficacy and reduced systemic exposure in a pulmonary fibrosis model compared with free drug. Supports broader potential of Roxadustat beyond anemia. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1921860/full
View on StockTwits ↗
Eons Everlasting@RespectedElderAug 3
$KYNB hiring senior medical director. “Demonstrated experience in oncology drug development with expertise in solid tumors.” So the oncology trial seems to be on its way. That leaves Roxadustat open. Partnership in the works? https://ats.rippling.com/kyntrabio/jobs/f6f02f81-1395-40e1-bb92-d97699b54334
View on StockTwits ↗
DEN K@ARKADIY_PAROVOZOVAug 3
$KYNB Astellas is running a Phase 3 study of Roxadustat for anemia in children and teenagers with chronic kidney disease (NCT05970172). The trial is currently recruiting and evaluates efficacy and safety in patients aged 2–17 years. https://www.humanexasignals.com/signals/roxadustat-study-for-anemia-in-children-with-chronic-kidney-disease-initiated-by
View on StockTwits ↗
DEN K@ARKADIY_PAROVOZOVJul 31
$KYNB New retrospective study (published July 30, 2026) in British Journal of Clinical Pharmacology shows Roxadustat was more effective than rhEPO for post-transplant anemia in kidney transplant recipients at 6 months. Response rate: 94.4% vs 78.1%. Note: significant drug–drug interaction with tacrolimus (increased exposure). https://doi.org/10.1002/bcp.70713
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.